Given aberrant MNX1-AS1 expression as a common event in cancer cells, this suggests potential therapeutic opportunities to counter glycolysis in cancer cells via targeting the non-glycolytic functions of key enzymes such as PKM2. The gene discussed is PKM; the disease is cancer.